Abstract: In this brief, a frequency and pattern reconfigurable antenna using double layer petal shaped parasitic structure loaded with PIN diodes is proposed. The double layer parasitic structure ...
Abstract: Due to the sparse feature enhancement only concentrating on strong scatterers of target of interest, the conventional sparsity-driven synthetic aperture radar (SAR) imagery often encounters ...
Structure Therapeutics Inc. earns a Strong Buy rating following robust phase 2b data for oral GLP-1R agonist Aleniglipron in obesity. Aleniglipron achieved placebo-adjusted weight loss up to -15.3% at ...
Placebo-adjusted mean weight loss of 11.3% (27.3 lbs) with 120 mg dose in the 36-week Phase 2b ACCESS study with a 10.4% adverse event-related treatment discontinuation Placebo-adjusted mean weight ...
SAN FRANCISCO, Dec. 08, 2025 (GLOBE NEWSWIRE) -- Structure Therapeutics Inc. (NASDAQ: GPCR), a clinical-stage global biopharmaceutical company developing novel oral small molecule therapeutics for ...